Sector News

GSK CEO Andrew Witty says drugmakers need to be empathetic

September 19, 2016
Life sciences

Drugmakers need to learn empathy and not try to defend price hikes that make drugs inaccessible, Andrew Witty, the chief executive of British pharmaceutical giant GSK, told CNBC.

“In all circumstance, we need to be realistic and empathetic, we need to demonstrate better that we understand people are concerned about [drug pricing],” Witty told CNBC on the sidelines of the Singapore Summit 2016.

“I’m not, for a second, going to sit here and defend any historical pricing position,” he added.

Drug prices have come under scrutiny in recent months after Mylan received public backlash for the sharp price increases the Epipen, an injection device to treat fatal anaphylactic shocks from food allergies or insect bites. The price of a two-pack Epipen has risen to nearly $600, from just $100 in 2007.

Pharmaceutical companies have also been a favorite target of both Democrat candidate Hillary Clinton and GOP nominee Donald Trump during the 2016 presidential elections campaign.

Trump has even commented about the potential savings that the U.S. Medicare program could reap if it negotiates directly with drug-makers, something currently prohibited by law. Last September, Clinton tweeted about the “price gorging” of Daraprim, a treatment often used by HIV/AIDS patients, drawing attention to Martin Shkreli, the former CEO of Turing Pharmaceuticals which owns the drug.

“There is a real issue here on affordability… it almost doesn’t matter whether or not you can defend the price because if people can’t afford it, that’s what we have to focus on,” Witty said.

“[Drug] pricing always has to be taken in a very responsible mindset to get the balance right between access and reward for innovation,” he added.

By Pauline Chiou and Aza Wee Sile

Source: CNBC

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.